AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06549075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic support
Description: The modular intervention consists of three modules, including Dignity Therapy, CALM Therapy and Mindfulness-based training. According to the patient's preferences, the patient will be allocated to one of the three interventions, which will be conducted by trained therapists within two sessions.
Study NCT06549075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Specialized Palliative Consultation Service
Description: According to needs standard specialized palliative care will include support of symptom control, shared decision making/ advance care planning, network planning and support of relatives.
Study NCT06549075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Specialized Palliative Consultation Service
Description: According to needs standard specialized palliative care will include support of symptom control, shared decision making/ advance care planning, network planning and support of relatives.
Study NCT04376437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medical cannabis
Description: inhalation by using a Portable Metered-Dose Cannabis Inhaler
Study NCT04828863 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurocognitive testing
Description: Participants will undergo a battery of neurocognitive tests that examine intellectual, executive, and adaptive function. The tests will be given remotely via internet-based surveys.
Study NCT05918263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training Exercise Program
Description: Home-based, virtually supervised, aerobic exercise program of 48 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.
Study NCT06354166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unscheduled hospital admissions
Description: Unscheduled short-stay geriatric hospitalisations of people aged over 75 to their homes
Study NCT06354166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unscheduled hospital admissions
Description: Unscheduled short-stay geriatric hospitalisations of people aged over 75 to their homes
Study NCT06324682 — intervention group
Intervention type: DEVICE
Intervention: Cardiac pacing - Conventional RV pacing
Description: Implantation of devices for cardiac pacing/defibrillation
Study NCT06324682 — intervention group
Intervention type: DEVICE
Intervention: Cardiac pacing - Conduction System Pacing
Description: Implantation of devices for cardiac pacing/defibrillation
Study NCT06324682 — intervention group
Intervention type: DEVICE
Intervention: Cardiac pacing - Cardiac resynchronization therapy (pacing - CRTP - or defibrillation - CRTD)
Description: Implantation of devices for cardiac pacing/defibrillation
Study NCT06324682 — intervention group
Intervention type: DEVICE
Intervention: Cardiac pacing - Epicardial pacing
Description: Implantation of devices for cardiac pacing/defibrillation
Study NCT06324682 — intervention group
Intervention type: DEVICE
Intervention: Cardiac pacing - Leadless pacing
Description: Implantation of devices for cardiac pacing/defibrillation
Study NCT05564897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H101, Camrelizumab
Description: Patients receive a combination therapy of Camrelizumab 200 mg i.v. every 3 weeks with intravesical H101 with a dose of 5×10\*11 Vp weekly for 6 weeks for both induction and maintenance treatments up to 1 years.
Study NCT02006173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Xylocaine is a 2 % lidocaine hydrochloride contained liquid anesthesia
Study NCT02006173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT05423353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin Bath Therapy
Description: Device named 'Fizyowax 1300' (Fizyomed, Turkey).
Study NCT05862792 — intervention group
Intervention type: DRUG
Intervention: Liposomal bupivacaine
Description: We will inject liposomal bupivacaine into the surgical bed.
Study NCT05423353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy
Description: Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
Study NCT04742478 — intervention group
Intervention type: PROCEDURE
Intervention: Rotational Atherectomy
Description: Rotational atherectomy (RA) has been the most used atherectomy modality since its first inception in1988. RA uses high speed rotation (140,000 - 180,000 rpm) to ablate inelastic plaque, resulting in debris averaging 5µm in size24. The main focus of RA in the era of DES stent has been on plaque modification rather that plaque debulking with more papers showing improved PCI success rates.
Study NCT05604313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergonomic chinrest used with low shoulder rest (EC)
Description: Participants will play the violin using the ergonomic chinrest with a low Kun Super shoulder rest (EC) for two weeks before the test day (crossover study), measuring upper body kinematic and muscle activity. The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
Study NCT06349278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic resection and non-anatomic liver resections.
Description: Pancreatic resection and non-anatomic liver resections.
Study NCT05170009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baloxavir Marboxil
Description: Weight-adjusted Baloxavir Marboxil (40 mg for patients weighing \<80 kg and 80 mg for those weighing ≥80 kg) at baseline, day 4, and day 7.
Study NCT05170009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at baseline, day 4, and day 7.
Study NCT05170009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir 75 mg twice daily for 10 days.
Study NCT05170009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir 75 mg twice daily for 10 days.
Study NCT06202443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early PT
Description: Physical therapy delivered within the first three months after surgery.
Study NCT06202443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed PT
Description: Physical therapy delivered greater than 3 months after surgery.
Study NCT04970368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node procedure
Description: Excision of ALL mapped nodes and other suspicious nodes regardless of mapping and label by anatomic location
Study NCT04970368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective staging
Description: Intraoperative consultation (IOC)
Study NCT06179056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: assess the possible role of Salicylic acid, Isotretinoin, and N-acetylcysteine in improving the susceptibility of C. acne for Azithromycin and Doxycycline.
Description: Microbiological samples were collected from all patients for:~1. Isolation of C. acnes~2. Antibiotic susceptibility testing for C. acnes isolates against the most commonly used antibiotics in the treatment of acne(Azithromycin and Doxycycline) in the presence and absence of Salicylic acid, Isotretinoin, and N-acetylcysteine~3. Testing biofilm forming ability of C. acnes isolates in the presence and absence of Salicylic acid, Isotretinoin, and N-acetylcysteine
Study NCT05221242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Resin Cement vs Preheated Resin Composite
Description: For this study, variolink esthetic resin cement will be used to bond ceramic partial laminate veneers in one side of the maxillary anterior teeth (left or right upper incisors and canines), while, the other side will receive ceramic partial laminate veneers bonded with a preheated resin composite
Study NCT05807932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Study treatment consists of the conditioning therapy including 6 or 8 days of Venetoclax treatment.
Study NCT05807932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amsacrine
Description: Amsacrine is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
Study NCT05807932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Ara-C is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
Study NCT05807932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
Study NCT05038527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABM/P-15 bone graft
Description: RCT (single blinded) where the patients will be randomized into two groups. One group receiving the standard bone graft which is a mix of locally autologous harvested bone and a morselized femoral head (allogenic) and the other group will receive bone graft of anorganic bovine bone mineral coated with a bioactive peptide (ABM/P-15).
Study NCT06018779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryoultrasound therapy plus high-intensity laser therapy
Description: Group A received a daily rehabilitation treatment lasting 10 sessions for 10 consecutive sessions, consisting of high-intensity laser therapy and cryo-sound therapy.
Study NCT06018779 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: diathermy plus high-intensity laser therapy
Description: Group B received a daily rehabilitation treatment lasting 10 sessions for 10 consecutive sessions, consisting of high-intensity laser therapy and diathermy.
Study NCT05749757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: For Shangyitang acupoint, the needle will be inserted towards the direction of nasal tip horizontally to a depth of 10-20mm without any manipulation, and a pad will be adhered afterwards. For other acupoints, the needles will be inserted through adhesive pads to 10-20mm. Needles will be lifted, thrust, and twirled for 3 times to achieve deqi sensation, and will be manipulated every ten minutes during 30-minute maintenance.
Study NCT05749757 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
Study NCT05807932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
Study NCT05119439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone + 2 doses of misoprostol 800 mcg
Description: Will use a mifepristone-misoprostol regimen of: 200 mg mifepristone followed in 24-48 hours by a first dose of 800 µg misoprostol buccally and then in another 4 hours by a second dose of 800 µg misoprostol buccally. For buccal administration of misoprostol, participants will place 2 misoprostol tablets in each cheek and hold them for 20-30 minutes, after which they will swallow any remnants.
Study NCT05286957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant tislelizumab and chemotherapy for MRD+ patients
Description: MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)
Study NCT05286957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant tislelizumab and chemotherapy for MRD+ patients
Description: MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)
Study NCT05286957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant tislelizumab and chemotherapy for MRD+ patients
Description: patients receive adjuvant tislelizumab and chemotherapy regardless of MRD status
Study NCT05286957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy for MRD- patients
Description: MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to ≤4 cycles
Study NCT06214364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation
Description: Active Anodal Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex of the affected or most affected hemisphere during 10 20 minute-sessions at 2 miliamps.~The tDCS stimulator device will be used by an experienced physical therapist by a saline-soak pair of surface electrodes. The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1.~While the tDCS stimulation is administered, virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation.
Study NCT06214364 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The electrodes will be placed in the same position as for the Primary Motor Cortex stimulation, as in the experimental group. Current will be applied for 30 seconds in the beginning and at the end for securing the blinding.~While the sham tDCS stimulation is administered virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation.
Study NCT05486780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Window
Description: For the digital window, a regal brand, 43R654FC, 43-inch (109 cm) television was used. A three-dimensional frame was built to give the appearance of a window around the television. For the digital window, a regal brand, 43R654FC, 43-inch (109 cm) television was used. A three-dimensional frame was built to give the appearance of a window around the television. Data collection will be completed by the researcher completing the Day and Night Perception Form and the Richards Campbell Sleep Scale (Post-Test) on the 1st, 2nd, and 3rd days of post-op for the patients in the experimental group who are in the field of view of the digital window.
Study NCT06506474 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Provision of any of six different low-value health services for treatment of bronchiolitis
Description: This prospective observational will have six separate primary outcomes acting as exposures, (or interventions).The exposures are the the provision of any of the six low-value health services: 1) respiratory virus testing; 2) chest x-ray; 3) continuous pulse oximetry; 4) short-acting beta-agonists; 5) systemic corticosteroids; and 6) antibiotics.
Study NCT06122779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986435
Description: Specified dose on specified days
Study NCT06122779 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT04925401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Information brochure will be created on the basis of information given by the French pediatric network Courlygone and the French National Authority for Health.
Description: An information brochure on fever in children and how to deal with a paediatric febrile episode and usual medical management.
Study NCT06392087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Patients ≥ 18 years of age (using a waiver of consent process) Pain score ≥ 4 on the verbal numeric pain rating scale (NPRS) traumatic injury (defined as: physical injuries of sudden onset and severity which requires immediate medical attention) Unaltered (Glasgow Coma Scale (GCS) ≥ 14) Normotensive (systolic blood pressure ≥100) Treated and transported
Study NCT06392087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Patients ≥ 18 years of age (using a waiver of consent process) Pain score ≥ 4 on the verbal numeric pain rating scale (NPRS) traumatic injury (defined as: physical injuries of sudden onset and severity which requires immediate medical attention) Unaltered (Glasgow Coma Scale (GCS) ≥ 14) Normotensive (systolic blood pressure ≥100) Treated and transported
Study NCT05844046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab, tremelimumab, bevacizumab
Description: durvalumab, tremelimumab and bevacizumab will be administered in the respective arms either as up-front triple treatment or as combined treatment with durvalumab and tremelimumab followed by the addition of bevacizumab
Study NCT05679206 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography images
Description: Transthoracic echocardiographic (Vivid E95) performed in all included patients between three months and three years after delivery.~* Left ventricular ejection fraction,~* Left ventricular mass index,~* Septal and lateral mitral annular E-wave velocity assessed by tissue Doppler,~* Tricuspid annular plane systolic excursion,~* Left atrial volume index,~* Right ventricle to right atrium (RV/RA) gradient
Study NCT05679206 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour ambulatory blood pressure monitoring
Description: Twenty-four-hour ABPM performed between three months and three years after delivery using validated recorders (Spacelabs model 90217, USA)
Study NCT04175964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: The ketogenic diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
Study NCT04175964 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: caloric diet with Metformin
Description: The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet with Metformin for 8 weeks.
Study NCT04175964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric diet
Description: The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
Study NCT06302374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2001
Description: intramuscular injection
Study NCT05504109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mitral valve replacement through full sternotomy approach.
Description: compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
Study NCT05504109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mitral valve replacement through right mini thoracotomy approach.
Description: compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
Study NCT06302374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intramuscular injection
Study NCT05046327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag 20 mg Oral Tablet
Description: Avatrombopag administered at a frequency to maintain a target platelet count between ≥50 and ≤150×10⁹/L
Study NCT06173180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOT
Description: In the Transobturator Tape-TOT operation, the anterior vaginal wall is incised 2 cm sagittal 1.5 cm below the urethra in the dorsal lithotomy position and the paraurethral areas are separated by sharp and blunt dissection and the ischiopubic bone is reached with the finger. The skin is incised so as to remain 1 cm lateral to the ischiopubic ramus on the line passing through the clitoris, and the synthetic tape is placed from outside to inside with special inclined trocars, passing under the urethra close to the medial part of the obturator foramen. Cystoscopy is not performed during the procedure. The vagen mucosa is sutured and the procedure is terminated by inserting a urethral foley catheter. The urethral catheter is removed on postoperative day 1 after the investigator evaluates the patient.
Study NCT06173180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VACS-D
Description: The VACS-Minifiks procedure is a vaginal application of a natural tissue repair procedure whose efficacy has been proven in the abdominal route. The second difference is that the procedure is performed through a single incision instead of the three incisions used in the Transobturator Tape-TOT operation. Thus, the same goal will be achieved in a less invasive way without placing an artificial permanent implant. There is no difference in parameters such as anesthesia, operation time, and discharge time.
Study NCT06302374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HTIG
Description: intramuscular injection
Study NCT06302374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid
Description: intramuscular injection
Study NCT05615415 — intervention group
Intervention type: DRUG
Intervention: PET Tracer
Description: Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.